Individualized cancer immunotherapy

EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Thursday, March 26, 2020 - 8:42pm

EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.

Key Points: 
  • EpiVax Oncology, Inc ., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic cancer vaccines.
  • Previously, the process to create an a personalized vaccine starting from tumor biopsy took at least 12 to 18 weeks.
  • With a personalized cancer vaccine process under 4 weeks, we can safely create a vaccine to treat all stages of aggressive cancer including in the neoadjuvant, adjuvant and metastatic setting.
  • EpiVax Oncology's personalized vaccine design platform, Ancer, incorporates the world-class EpiMatrix system and the innovative JanusMatrix tool, which were exclusively licensed to EpiVax Oncology by EpiVax.

BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

Thursday, January 16, 2020 - 12:30pm

Neon is a biotechnology company developing novel neoantigen-based T cell therapies.

Key Points: 
  • Neon is a biotechnology company developing novel neoantigen-based T cell therapies.
  • I am particularly excited about the adoptive T cell and neoantigen TCR therapies being developed by Neon, which are complementary to our pipeline and our focus on solid tumors.
  • Neon has deep expertise in the development of neoantigen therapies, with both vaccine and T-cell capabilities.
  • Neon is also advancing a precision T cell therapy program targeting shared neoantigens in genetically defined patient populations.

BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

Thursday, January 16, 2020 - 12:30pm

Neon is a biotechnology company developing novel neoantigen-based T cell therapies.

Key Points: 
  • Neon is a biotechnology company developing novel neoantigen-based T cell therapies.
  • I am particularly excited about the adoptive T cell and neoantigen TCR therapies being developed by Neon, which are complementary to our pipeline and our focus on solid tumors.
  • Neon has deep expertise in the development of neoantigen therapies, with both vaccine and T-cell capabilities.
  • Neon is also advancing a precision T cell therapy program targeting shared neoantigens in genetically defined patient populations.

Avidea Technologies Utilizes GenScript's Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine

Wednesday, January 15, 2020 - 12:30pm

PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.

Key Points: 
  • PISCATAWAY, N.J., Jan. 15, 2020 /PRNewswire/ -- GenScript , a world leading biotechnology company, announced its support today of Avidea Technologies' efforts to develop a groundbreaking peptide-based personalized cancer vaccine.
  • Developing and validating SNP-7/8a as a personalized cancer vaccine required synthesis of hundreds of unique neoantigen peptides, which were successfully synthesized by Genscript in support of this work.
  • The publication is particularly timely as personalized cancer vaccines are garnering increasing attention among the scientific and medical community as important components to enabling precision immuno-oncology.
  • To support this work, GenScript synthesized hundreds of challenging neoantigen peptides that were selected to have a wide range of properties, including neoantigen peptides with extremes of net charge and hydrophobicity, which was instrumental to enabling Avidea and NIH scientists to validate the generalizability of the SNP-7/8a platform as a personalized cancer vaccine.